{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-107288","form_type":"8-K","ticker":"AGEN","cik":"0001098972","company_name":"AGENUS INC","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.537175+00:00","generated_at":"2026-05-15T11:24:19.373344+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Agenus reports $4.2M initial BOT+BAL revenue; net loss narrows to $3.1M in FY2025","bullets":["Pre-commercial product revenue of $4.2M from early access programs in France and paid NPP across 30+ countries.","BOT+BAL shows 42% two-year OS and ~21-month median OS in heavily pretreated MSS mCRC; Phase 3 BATTMAN trial initiated.","France AAC expanded to ovarian cancer and sarcoma in January 2026; 200+ physician inquiries received globally.","Zydus collaboration provided $91M upfront capital; $20M contingent payment triggered in March 2026 for manufacturing.","Q4 2025 operating income $14.4M; full year net loss $3.1M vs prior year; other revenue $110M (non-cash royalty)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-107288","json":"https://secwatch.observer/filing/0001193125-26-107288.json","markdown":"https://secwatch.observer/filing/0001193125-26-107288.md","text":"https://secwatch.observer/filing/0001193125-26-107288.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1098972/000119312526107288/0001193125-26-107288-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1098972/000119312526107288/agen-20260316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:24:19.373344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5de3550b2de0e7721299dc2874eff90c7ee9bcb0","claim":"AGENUS INC reported financial results for the fourth quarter ended December 31, 2025.","evidence_excerpt":"On March 16, 2026, Agenus Inc. announced its financial results for the quarter and year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1098972/000119312526107288/0001193125-26-107288-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d6a2fbb7892c4b5690ed16cf9ebd23d002a4be51","claim":"AGENUS INC reported financial results for the full year ended December 31, 2025.","evidence_excerpt":"On March 16, 2026, Agenus Inc. announced its financial results for the quarter and year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1098972/000119312526107288/0001193125-26-107288-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}